Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non–small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. METHODS: Patients with s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Oncol Pract
Prif Awduron: Carroll, Nikki M., Delate, Thomas, Menter, Alex, Hornbrook, Mark C., Kushi, Lawrence, Aiello Bowles, Erin J., Loggers, Elizabeth T., Ritzwoller, Debra P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2015
Pynciau:
Health Care Delivery
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4575400/
https://ncbi.nlm.nih.gov/pubmed/26060223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.2014.002980
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg